VolitionRX (VNRX) investor relations material

Executive summary

• Revenue for Q1 2026 reached $1.0 million, up from $0.2 million year-over-year, driven by deferred revenue recognition from the Nu.Q Vet agreement with Heska and increased product sales.

• Operating expenses increased to $6.3 million from $5.8 million, reflecting severance, higher R&D, and administrative costs.

• Net loss for Q1 2026 was $6.7 million, a 22% increase from $5.5 million in Q1 2025, mainly due to higher expenses and non-cash charges related to convertible notes.

• Significant progress was made across all product pillars, including Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-Seq, with new clinical milestones and expanded commercial discussions.

• Cash and equivalents rose to $3.1 million, supported by $5.4 million from equity sales, $1.9 million from a convertible note, and $1 million in non-dilutive funding.

Financial highlights

• Revenue increased 300% year-over-year to $1.0 million, primarily due to deferred revenue recognition and product sales.

• Operating loss decreased by 3% year-over-year.

• Net cash used in operations was $5.3 million, up from $4.3 million, partly due to supplier payment timing.

• Net cash provided by financing activities was $7.6 million, reflecting proceeds from equity and convertible note issuances.

• Non-dilutive funding since inception exceeds $25 million.

Outlook and guidance

• No revenue guidance for 2026 due to unpredictability at this commercialization stage.

• Management expects continued operating losses and negative cash flows as commercialization and clinical development efforts expand.

• Additional funding will be required to sustain operations and meet debt obligations; recent capital raises provide only short-term relief.

• Anticipation of a $5 million milestone payment upon publication of the feline cancer study.

• Focus remains on licensing, distribution deals, and cost control to extend cash runway.